PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis.
Phase 1
- Conditions
- Progressive Pulmonary Fibrosis (PPF)MedDRA version: 21.0Level: PTClassification code: 10037383Term: Pulmonary fibrosis Class: 100000004855Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Registration Number
- CTIS2023-503686-26-00
- Lead Sponsor
- St Antonius Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
= 18 years of age, New diagnosis of PPF, A minimum of 20% of lung parenchyma is aberrant (fibrosis, inflammation or both), MDT indication for treatment with either immunosuppressive drugs or antifibrotic drug
Exclusion Criteria
Prior or current treatment with antifibrotic drugs, Active malignancy, Inability to undergo a PET/CT at the Sint Antonius Hospital, Incapacity to give informed consent personally, Pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method